Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Mer­ck and As­traZeneca are hop­ing to ex­pand the la­bel of their MEK in­hibitor Kosel­u­go to cer­tain adult pa­tients with neu­rofi­bro­mato­sis type 1 fol­low­ing a suc­cess­ful …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER